STAAR SURGICAL CO — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 71/100
What the filing says
STAAR Surgical reported Q2 2026 net sales of $93.5M (up 111% YoY from $44.3M), with net income of $8.1M ($0.16/diluted share) vs. loss of $16.8M ($0.34/share) YoY. China sales surged to $52.3M (56% of total, up 100%+ YoY), while ex-China sales grew 6% to $41.2M. Gross margin improved to 74.5% vs. 74.0% YoY. Adjusted EBITDA was $20.0M ($0.39/share) vs. loss of $14.8M ($0.30/share) prior year. CEO Warren Foust appointed; CFO Deborah Andrews promoted to EVP. Cash position improved to $181.5M (vs. $163.9M Q1 2026).
Why this rating
111% revenue growth + pivot from loss to profit + 56% China concentration + strong margin expansion significant for $883.9M company, but execution risks on China seasonality and tariff headwinds remain.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.